Jeffrey La Rosa

Stock Analyst at Leerink Partners

(1.33)

# 1,911

Out of 4,415 analysts

2

Total ratings

100%

Success rate

2.46%

Average return

Main Sectors:

Top Industries:

Biotechnology Drug Manufacturers - General

2 Stocks

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	PYXS Pyxis Oncology	Initiates: Outperform	$12	$4.38	+173.97%	1	Jan 23, 2024
	MRK Merck & Co.	Maintains: Outperform	$110 → $112	$127.51	-12.16%	1	Oct 28, 2022

Pyxis Oncology

Jan 23, 2024

Initiates: Outperform

Price Target: $12

Current: $4.38

Upside: +173.97%

Merck & Co.

Oct 28, 2022

Maintains: Outperform

Price Target: $110 → $112

Current: $127.51

Upside: -12.16%